A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Cameron J. Turtle(The University of Sydney), Stanley Dai(Nektar Therapeutics (United States)), Saurabh Dahiya(Stanford University), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Olalekan O. Oluwole(Vanderbilt University), Sohail A. Chaudhry(Nektar Therapeutics (United States)), Joseph P. McGuirk(University of Kansas Medical Center), Mario Q. Marcondes(Nektar Therapeutics (United States)), Mary Tagliaferri(Nektar Therapeutics (United States)), Christie Fanton(Nektar Therapeutics (United States)), Zachary Lee(Nektar Therapeutics (United States)), Peter A. Riedell(University of Chicago), Neha Dixit(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 1
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k